The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.
If you are not happy with the results below please do another search
50 search results for:
AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe, and a positive clinical trial update.
Shares of Angion Biomedica Corp. are falling fast after the company announced it had discontinued a mid-stage study of an oral tyrone kinase inhibitor in patients with primary proteinuric kidney diseases due to safety reasons. And Novo Nordisk also hit a wall, reporting that its diabetes drug Ozempic (semaglutide) failed to inprove liver fibrosis in NASH-related cirrhosis.
Ashfield and Huntsworth unite their full suite of advisory, medical, marketing, communications and patient and stakeholder engagement services to create Inizio, a strategic partner to health and life science companies throughout the life cycle of their drug products.
The agency’s decision came after researchers found cases of drug-induced liver injury in some patients.
The continent has no vaccines for monkeypox and test kits are in short supply, international health agencies said on Thursday, warning that richer countries already appeared to be hoarding vaccines.
Pfizer Inc. and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.
Providers continue to adapt to the new care models to patients’ needs. As the pandemic wreaked havoc across the United States, healthcare providers started deploying various health IT solutions to address emerging challenges. They aimed to reduce the load on doctors and protect clinicians and patients from the virus exposure.
Pfizer said it submitted a New Drug Application for Paxlovid to the FDA for the treatment of COVID-19 in vaccinated and unvaccinated people at high risk for progression to severe illness.
AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.